Shots: The approval is based on P-III ARRIVAL study results assessing Kalydeco in 25 children with CF who have either of 10 mutations in CFTR gene (G551D, G178R, S549N, S549R, […]readmore
Tags : Vertex’s Kalydeco
Regulatory
Vertex‘s Orkambi (lumacaftor/ivacaftor) Receives Health Canada Approval for Cystic Fibrosis
Shots: The approval is based on P-III study results assessing Orkambi in 60 patients with CF, who have two copies of the F508del CFTR mutation aged 6 to 11 years for 24 wks. […]readmore